The impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: A meta-analysis

Diabetes Research and Clinical Practice

Volumn 90, Issue 3, 2010, Pages 279-287

  Zhao, Yulan ^a   He, Xuelian ^b   Huang, Chengjin ^c   Fu, Xiaonan ^a   Shi, Xuegui ^a   Wu, Ying ^a   Han, Yijie ^a   Li, Naishi ^c   Wu, Yanxiang ^b   Heng, Chew Kiat ^d  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b Wuhan Children's Hospital   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

C reactive protein; Coronary artery disease; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLITAZONE DERIVATIVE; PIOGLITAZONE; ROSIGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG MECHANISM; DRUG RESPONSE; HUMAN; INFORMATION RETRIEVAL; META ANALYSIS; PREDICTION; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW;

C-REACTIVE PROTEIN; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 78649477674     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.09.011     Document Type: Article

References (31)

1. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004, 351:1106-1118.
2. Vamecq J., Latruffe N. Medical significance of peroxisome proliferator-activated receptors. Lancet 1999, 354:141-148.
3. Zinn A., Felson S., Fisher E., Schwartzbard A. Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 2008, 31:397-403.
4. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
5. Home P.D., Pocock S.J., Beck-Nielsen H., Curtis P.S., Gomis R., Hanefeld M., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
6. Bari D.S.G. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503-2515.
7. Graham D.J., Ouellet-Hellstrom R., MaCurdy T.E., Ali F., Sholley C., Worrall C., et al. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010, 304:411-418.
8. Bertrand O.F., Poirier P., Rodes-Cabau J., Rinfret S., Title L.M., Dzavik V., et al. Cardiometabolic effects of rosiglitazone in patients with type 2 diabetes and coronary artery bypass grafts: a randomized placebo-controlled clinical trial. Atherosclerosis 2010, 211:565-573.
9. Rabol R., Boushel R., Almdal T., Hansen C.N., Ploug T., Haugaard S.B., et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:806-814.
10. Willerson J.T., Ridker P.M. Inflammation as a cardiovascular risk factor. Circulation 2004, 109:II2-II10.
11. Bisoendial R.J., Kastelein J.J.P., Stroes E.S.G. C-reactive protein and atherogenesis: from fatty streak to clinical event. Atherosclerosis 2007, 195:e10-e18.
12. Genser B., Grammer T.B., Stojakovic T., Siekmeier R., Marz W. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther 2008, 46:497-510.
13. Qayyum R., Adomaityte J. Meta-analysis of the effect of thiazolidinediones on serum C-reactive protein levels. Am J Cardiol 2006, 97:655-658.
14. Zhao Y., He X., Shi X., Huang C., Liu J., Zhou S., et al. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm Res 2010, 59:323-334.
15. Liu T., Li G., Li L., Korantzopoulos P. Association between C-reactive protein and recurrence of atrial fibrillation after successful electrical cardioversion: a meta-analysis. J Am Coll Cardiol 2007, 49:1642-1648.
16. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
17. Staniloae C., Mandadi V., Kurian D., Coppola J., Bernaski E., El-Khally Z., et al. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Cardiology 2007, 108:164-169.
18. Kasai T., Miyauchi K., Yokoyama T., Kajimoto K., Surniyoshi K., Kubota N., et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 2008, 197:612-619.
19. Naoumova R.P., Kindler H., Leccisotti L., Mongillo M., Khan M.T., Neuwirth C., et al. Pioglitazone improves myocardial blood flow and glucose utilization in nondiabetic patients with combined hypedipidemia-a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2007, 50:2051-2058.
20. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes-The PERISCOPE randomized controlled trial. JAMA 2008, 299:1561-1573.
21. Yasuda S., Kobayashi H., Iwasa M., Kawamura I., Sumi S., Narentuoya B., et al. Antidiabetic drug pioglitazone protects the heart via activation of PPAR-gamma receptors, PI3-kinase, Akt, and eNOS pathway in a rabbit model of myocardial infarction. Am J Physiol Heart Circ Physiol 2009, 296:H1558-H1565.
22. Sidhu J.S., Cowan D., Tooze J.A., Kaski J.-C. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004, 147:e25.
23. Sidhu J.S., Kaposzta Z., Markus H.S., Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004, 24:930-934.
24. Choi D., Kim S.-K., Choi S.-H., Ko Y.-G., Ahn C.-W., Jang Y., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
25. Yu J., Jin N., Wang G., Zhang F., Mao J., Wang X. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism 2007, 56:1396-1401.
26. Bertrand O.F., Poirier P., Rodes-Cabau J., Rinfret S., Title L., Dzavik V., et al. A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the Vein-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial. Can J Cardiol 2009, 25:509-515.
27. Ratner R.E., Cannon C.P., Gerstein H.C., Nesto R.W., Serruys P.W., van Es G.A., et al. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. Am Heart J 2008, 156:1074-1079.
28. Goldberg R.B., Kendall D.M., Deeg M.A., Buse J.B., Zagar A.J., Pinaire J.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547-1554.
29. Mittermayer F., Schaller G., Pleiner J., Krzyzanowska K., Kapiotis S., Roden M., et al. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. J Clin Endocrinol Metab 2007, 92:2574-2580.
30. Raji A., Gerhard-Herman M.D., Williams J.S., O'Connor M.E., Simonson D.C. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. Diabet Med 2006, 23:537-543.
31. Abbasi F., Farin H.M.F., Lamendola C., McGraw L., McLaughlin T., Reaven G.M. Pioglitazone administration decreases cardiovascular disease risk factors in insulin-resistant smokers. Metabolism 2008, 57:1108-1114.